| Catalog No. | VK623066 |
|---|
| Species reactivity | Zaireebolavirus(ZEBOV) |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Human |
|---|
| Isotype | IgG1, kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | Envelope glycoprotein, GP1,2, GP, Shed GP, GP1,2-delta, GP1, GP2, GP |
|---|
| Concentration | 3.7mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | Q05320 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -631°C. |
|---|
| Alternate Names | REGN-3470-3471-3479,REGN-3470/REGN-3471/REGN-3479,REGN-EB3,REGNEB3,Inmazeb(atoltivimab,maftivimab,odesivimab-ebgn),CAS:2135632-29-8 |
|---|
| Background | Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection. |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
